HBV Mutation Detail Information

> A181V Search Result


Mutation Information
Mutation Site A181V
Mutation Type Amino acid level
Gene/Protein/Region Type RT
Combined Mutation rt.N236T+rt.A181T+rt.A181V;rt.N236T+rt.A181V
Genotype/Subtype B;C
Relevant Drug adefovir dipivoxil (ADV);lamivudine (LAM);telbivudine (LDT);tenofovir (TDF)
Country China
Literature Information
PubMed PMID 28017671
Disease HBV infection
Published Year 2017
Journal Journal of global antimicrobial resistance
Title Analysis of the prevalence of drug-resistant hepatitis B virus in patients with antiviral therapy failure in a Chinese tertiary referral liver centre (2010-2014).
Author Meng T,Shi X,Gong X,Deng H,Huang Y,Shan X,Shan Y,Huang A,Long Q
Evidence The 3TC resistance rate increased from 39.8% in 2010 to 56.6% in 2013, before decreasing to 49.5% in 2014, evidence of a lagging effect of l-nucleoside consumption. M204I, N236T and L180M+M204V+V173L/S202G were the most common substitutions for l-nucleoside (3TC and LdT), ADV and ETV genotypic resistant phenotypes, respectively.

Contents
Description
Mutation Information Note
  • Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)
Literature Information Note
  • Evidence: sentence contains this mutation information in the citation